NewAmsterdam Pharma (NAMS) Leases (2022 - 2025)
NewAmsterdam Pharma (NAMS) has disclosed Leases for 4 consecutive years, with $185000.0 as the latest value for Q4 2025.
- Quarterly Leases fell 57.08% to $185000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $185000.0 through Dec 2025, down 57.08% year-over-year, with the annual reading at $185000.0 for FY2025, 57.08% down from the prior year.
- Leases hit $185000.0 in Q4 2025 for NewAmsterdam Pharma, down from $246000.0 in the prior quarter.
- In the past five years, Leases ranged from a high of $554000.0 in Q2 2024 to a low of $38000.0 in Q1 2024.
- Historically, Leases has averaged $279900.0 across 4 years, with a median of $277000.0 in 2025.
- Biggest YoY gain for Leases was 871.05% in 2025; the steepest drop was 57.08% in 2025.
- Year by year, Leases stood at $120000.0 in 2022, then plummeted by 54.17% to $55000.0 in 2023, then skyrocketed by 683.64% to $431000.0 in 2024, then crashed by 57.08% to $185000.0 in 2025.
- Business Quant data shows Leases for NAMS at $185000.0 in Q4 2025, $246000.0 in Q3 2025, and $308000.0 in Q2 2025.